Given the high potential of a myeloid cell-based therapeutic target for SD, we next sought to replace Hexb deficient microglia in Hexb-/- mice with Hexb sufficient cells from WT donors and assess the viability of microglial replacement as a treatment for SD. This evidence concerns the gene HEXB and Salla disease.